HCPLive Network

Admission for Syncope Increases Risk of Death, Cardio Events

 
WEDNESDAY, Dec. 12 (HealthDay News) -- Among patients without previous comorbidity admitted for syncope, there is a significant increased risk of all-cause mortality, stroke, and cardiovascular hospitalization, according to a study published online Dec. 12 in the Journal of the American College of Cardiology.

Martin Huth Ruwald, M.D., from Gentofte Hospital in Hellerup, Denmark, and colleagues used nationwide administrative registries to identify 37,017 patients with a first-time diagnosis of syncope and matched them in a 1:5 ratio with 185,085 control subjects. The median age was 47 years, and 47 percent were male.

The researchers found that in the syncope group there were 3,023 deaths (8.2 percent), yielding an event rate of 14.3 per 1,000 person-years (PY), compared with 14,251 deaths (7.1 percent) in the control population. There was a significantly increased risk of all-cause mortality (hazard ratio [HR], 1.06; 95 percent confidence interval, 1.02 to 1.10) in the syncope group. In addition, there were significantly increased rates of cardiovascular hospitalization events (26.5 per 1,000 PY; HR, 1.74); recurrent syncope events (45.1 per 1,000 PY); stroke events (6.8 per 1,000 PY; HR, 1.35); and pacemaker or implantable cardioverter-defibrillator events (4.2 per 1,000 PY; HR, 5.52).

"First admission for syncope in a population without previous comorbidity significantly predicts the risk of all-cause mortality, stroke, cardiovascular hospitalization, device implantation, and recurrent syncope," the authors write. "The study suggests that syncope in seemingly healthy persons may be a first symptom of a more severe underlying cardiovascular disease."

One author disclosed financial ties to the pharmaceutical industry.
 

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Further Reading
Results of a large international study known as SIGNIFY showed ivabradine offered no benefit to patients who had stable coronary artery disease without clinical heart failure (CHF).
Novartis plans to soon file a new drug application with the US Food and Drug Administration (FDA) for its investigational heart failure drug LCZ696. A report showing the drug works better than enalapril to prevent adverse cardiac events was released at the European Society of Cardiology Congress in Barcelona, Spain Aug. 30 and published online in the New England Journal of Medicine (NEJM).
Adolescent transgender patients face many challenges, as do the medical professionals who care for them. What is the best way to manage transgender youths? This is a complex question with answers that rely on a case-by-case, ethical approach
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.
Having regular family meals may help protect teens from the harmful mental health effects of "cyberbullying," a new study suggests. The study was published online Sept. 1 in JAMA Pediatrics.
A major demonstration project designed to gauge the effectiveness of bundled payments exposed the complications of implementing such a system. Officials say the 3-year study fizzled after participation waned and the number of applicable cases proved too few to be statistically relevant.
The quality of Americans' diets has improved somewhat but remains poor overall, and dietary disparity between the rich and poor is growing, a new study shows. Education also played a role in dietary quality, which was lowest and improved more slowly among people who had 12 years or less of school, according to the study published online Sept. 1 in JAMA Internal Medicine.
More Reading